日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Antibody targeting of E3 ubiquitin ligases for receptor degradation

抗体靶向E3泛素连接酶以降解受体

Hadir Marei # ,Wen-Ting K Tsai # ,Yee-Seir Kee # ,Karen Ruiz ,Jieyan He ,Chris Cox ,Tao Sun ,Sai Penikalapati ,Pankaj Dwivedi ,Meena Choi ,David Kan ,Pablo Saenz-Lopez ,Kristel Dorighi ,Pamela Zhang ,Yvonne T Kschonsak ,Noelyn Kljavin ,Dhara Amin ,Ingrid Kim ,Andrew G Mancini ,Thao Nguyen ,Chunling Wang ,Eric Janezic ,Alexander Doan ,Elaine Mai ,Hongkang Xi ,Chen Gu ,Melanie Heinlein ,Brian Biehs ,Jia Wu ,Isabelle Lehoux ,Seth Harris ,Laetitia Comps-Agrar ,Dhaya Seshasayee ,Frederic J de Sauvage ,Matthew Grimmer ,Jing Li ,Nicholas J Agard ,Felipe de Sousa E Melo

Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

靶向肿瘤衍生的可溶性 NKG2D 配体 sMIC 的抗体可对 CD8 T 细胞进行双重共刺激,并使 sMIC+ 肿瘤对 PD1/PD-L1 阻断疗法产生反应

Jinyu Zhang, Pablo Saenz-Lopez Larrocha, Bin Zhang, Derek Wainwright, Payal Dhar, Jennifer D Wu